"These Phase 1 data demonstrate that vaccination with mRNA-1273 elicits a robust immune response across all dose levels and clearly support the choice of 100 ug in a prime and boost regimen as the optimal dose for the Phase 3 study," Moderna's chief medical officer, Tal Zaks, said in a statement. "We look forward to beginning our Phase 3 study of mRNA-1273 this month to demonstrate our vaccine's ability to significantly reduce the risk of Covid-19 disease."
In May, Moderna announced that the phase I trial of its Covid-19 vaccine has shown positive early results.
Moderna, based in Cambridge, Massachusetts had announced that the vaccine developed neutralising antibodies to the virus at levels reaching or exceeding the levels seen in people who have naturally recovered from Covid-19, reported CNN.
Earlier Tuesday, Moderna announced it would begin its late-stage trial for its vaccine on July 27.